Replicate Bioscience
Replicate Bioscience is pioneering self-replicating RNA (srRNA) technology to revolutionize medicine by developing treatments for infectious diseases, cancer, autoimmune, and inflammatory disorders. Their platform leverages advanced srRNA vectors for high protein expression, durability, and broad therapeutic applications, aiming to expand the reach of RNA therapeutics globally.
Industries
Nr. of Employees
small (1-50)
Patents
Compositions and methods for the prevention and treatment of rabies virus infection
US-11730804-B1
View DetailsCompositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
US-11510975-B1
View Details
Compositions and methods for the prevention and treatment of rabies virus infection
US-11730804-B1
View DetailsCompositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses
US-11510975-B1
View DetailsProducts
srRNA rabies vaccine (clinical candidate, Phase 1)
A prophylactic self‑replicating RNA vaccine candidate evaluated in a Phase 1 study to assess safety, tolerability, and immunogenicity; achieved virus‑neutralizing antibody titers meeting WHO surrogate of protection at ultra‑low doses in initial clinical results.
srRNA precision immuno-oncology candidate (preclinical/IND‑enabling)
Off‑the‑shelf srRNA immunotherapy designs intended to prime immune responses against acquired resistance mutations in tumors to be used in combination with standard‑of‑care targeted therapies.
srRNA multi‑protein expression candidate (protein replacement proof‑of‑concept)
srRNA constructs demonstrating the ability to encode and express multiple therapeutic proteins from a single vector for applications such as cytokine co‑expression, protein replacement, or secreted biologics.
srRNA rabies vaccine (clinical candidate, Phase 1)
A prophylactic self‑replicating RNA vaccine candidate evaluated in a Phase 1 study to assess safety, tolerability, and immunogenicity; achieved virus‑neutralizing antibody titers meeting WHO surrogate of protection at ultra‑low doses in initial clinical results.
srRNA precision immuno-oncology candidate (preclinical/IND‑enabling)
Off‑the‑shelf srRNA immunotherapy designs intended to prime immune responses against acquired resistance mutations in tumors to be used in combination with standard‑of‑care targeted therapies.
srRNA multi‑protein expression candidate (protein replacement proof‑of‑concept)
srRNA constructs demonstrating the ability to encode and express multiple therapeutic proteins from a single vector for applications such as cytokine co‑expression, protein replacement, or secreted biologics.
Services
Integrated development from srRNA vector design and preclinical testing through IND‑enabling studies and early-phase clinical trials, coordinated with external manufacturing and formulation partners.
Partnership management and licensing to access lipid nanoparticle technologies, scalable manufacturing platforms, and CDMO services for clinical and commercial production of srRNA therapeutics.
Integrated development from srRNA vector design and preclinical testing through IND‑enabling studies and early-phase clinical trials, coordinated with external manufacturing and formulation partners.
Partnership management and licensing to access lipid nanoparticle technologies, scalable manufacturing platforms, and CDMO services for clinical and commercial production of srRNA therapeutics.
Expertise Areas
- srRNA platform engineering
- Vaccine development and clinical translation
- Precision immuno-oncology
- Bioprocessing and GMP scale-up for long RNAs
Key Technologies
- Self-replicating RNA vectors
- Lipid nanoparticle (LNP) delivery
- Microfluidic LNP manufacturing
- Multi‑cargo RNA encoding